SG11202111012QA - Trispecific binding proteins, methods, and uses thereof - Google Patents

Trispecific binding proteins, methods, and uses thereof

Info

Publication number
SG11202111012QA
SG11202111012QA SG11202111012QA SG11202111012QA SG11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA
Authority
SG
Singapore
Prior art keywords
methods
binding proteins
trispecific binding
trispecific
proteins
Prior art date
Application number
SG11202111012QA
Other languages
English (en)
Inventor
Joerg Birkenfeld
Gary J Nabel
Zhi-Yong Yang
Huawei Qiu
Joerg Regula
Edward Seung
Ronnie Wei
Lan Wu
Zhen Xing
Ling Xu
Catherine Prades
Tarik Dabdoubi
Béatrice Cameron
Cendrine Lemoine
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11202111012QA publication Critical patent/SG11202111012QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202111012QA 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof SG11202111012QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831572P 2019-04-09 2019-04-09
EP19306261 2019-10-02
PCT/US2020/027320 WO2020210392A1 (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Publications (1)

Publication Number Publication Date
SG11202111012QA true SG11202111012QA (en) 2021-11-29

Family

ID=72751423

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111012QA SG11202111012QA (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Country Status (13)

Country Link
EP (1) EP3953388A1 (zh)
JP (1) JP2022527994A (zh)
KR (1) KR20210149141A (zh)
CN (1) CN113950484A (zh)
AU (1) AU2020272839A1 (zh)
BR (1) BR112021019915A2 (zh)
CA (1) CA3136821A1 (zh)
CO (1) CO2021014918A2 (zh)
IL (1) IL286929A (zh)
MX (1) MX2021012386A (zh)
SG (1) SG11202111012QA (zh)
TW (1) TW202104261A (zh)
WO (1) WO2020210392A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024077118A2 (en) * 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI803876B (zh) * 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2016033690A1 (en) * 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
PE20171764A1 (es) * 2015-01-23 2017-12-21 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
WO2016205531A2 (en) * 2015-06-17 2016-12-22 Genentech, Inc. Anti-her2 antibodies and methods of use
BR112018008011A2 (pt) 2015-10-25 2018-10-30 Sanofi proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
CN117964758A (zh) * 2017-10-10 2024-05-03 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
US11530268B2 (en) * 2018-10-09 2022-12-20 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection

Also Published As

Publication number Publication date
JP2022527994A (ja) 2022-06-07
CO2021014918A2 (es) 2021-11-19
AU2020272839A1 (en) 2021-12-02
TW202104261A (zh) 2021-02-01
CA3136821A1 (en) 2020-10-15
CN113950484A (zh) 2022-01-18
MX2021012386A (es) 2022-01-18
EP3953388A1 (en) 2022-02-16
KR20210149141A (ko) 2021-12-08
BR112021019915A2 (pt) 2021-12-07
WO2020210392A1 (en) 2020-10-15
IL286929A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
PT3443006T (pt) Proteínas de ligação triespecíficas e/ou trivalentes
IL277398A (en) PD-L1 binding epimers and related uses thereof
EP3452089A4 (en) BISPECIFIC BINDING PROTEINS AND USES THEREOF
IL278943A (en) Multi-specificity binding proteins and improvements thereof
IL265489B (en) Recombinant binding proteins and their uses
EP3655432A4 (en) BINDING PROTEIN 1
IL268755A (en) HER2, NKG2D, and CD16 binding proteins
EP3613772A4 (en) SPECIFIC BINDING MOLECULE FOR LRIG-1 PROTEIN AND ITS USE
IL268567A (en) BCMA, NKG2D and CD16 binding proteins
EP3689893A4 (en) IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE
IL284664A (en) Multispecific binding proteins
EP3515948A4 (en) COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF
EP3380514A4 (en) GDF131-BINDING PROTEINS AND USES THEREOF
ZA202103259B (en) Modified cas9 protein, and use thereof
EP3705121A4 (en) EMOPAMIL BINDING PROTEIN BINDING AGENT AND ITS USE
EP3689894A4 (en) IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE
EP3882266A4 (en) LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE THEREOF
IL284317A (en) FAB pseudoproteins are multispecific binding proteins
EP3700571A4 (en) ALK7-BINDING PROTEINS AND USES THEREOF
IL304317A (en) tgf–beta–rii binding proteins
IL286929A (en) Tri-specific binding proteins, methods, and their use
IL289145A (en) il1rap binding proteins
EP4077385A4 (en) CXCL10-BINDING PROTEINS AND USES THEREOF
EP3976630A4 (en) ACTRII-BINDING PROTEINS AND THEIR USES
EP3973550C0 (en) PEPTIDE IONOGEL, COMPOSITION, METHODS AND USES THEREOF